Sarepta Therapeutics (SRPT) shares were boosted Tuesday by analysts with RBC Capital Markets. The team at RBC upgraded the stock to OUTPERFORM from SECTOR PERFORM, based on the accelerated FDA approval of its Duchenne muscular-dystrophy treatment, which analysts say could be a "major game changer." Sarepta shares have more than doubled over the past month, following a challenging start of 2016 for the drugmaker.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.